Mallun Yen, serving as a director at Everpure, Inc. (NASDAQ:P), has executed a notable reduction in her personal equity stake within the medical device manufacturer. On June 22, 2026, Yen sold 4,735 shares of the company’s Class A Common Stock. The transaction was valued at a total of $364,121, executed through sales occurring at prices ranging between $76.83 and $76.97 per share. The weighted average price for these transactions was recorded at $76.90.
Following the completion of this sale, Yen’s direct ownership in Everpure stands at 43,281 shares of common stock. The market reaction to this insider activity has been marked by a decline in the stock price since the transaction date. As of the latest data, the stock is trading at $72.79, representing a decrease from the $76.90 average sale price observed during the transaction.
Valuation analysis provided by InvestingPro suggests that the company may currently be overvalued relative to its calculated Fair Value. This valuation context may offer insight into the insider's decision to reduce holdings. Everpure is currently trading at a price-to-earnings (P/E) ratio of 110.61, a figure that reflects a premium valuation. This premium persists despite the company reporting strong revenue growth of 21%.
The insider sale occurs against a backdrop of strong operational performance. Everpure reported a robust first quarter, with revenue reaching $1.053 billion. This figure represents a 35% increase compared to the same period last year. The growth was partially attributed to increased customer demand and higher pricing strategies implemented in response to supply chain component shortages.
The company’s financial results exceeded market expectations on both revenue and earnings fronts. Consequently, Everpure raised its fiscal 2027 revenue guidance. The new midpoint forecast indicates 22% growth, an upward revision from the previous forecast of 19%.
Analyst firms have responded positively to these developments. Piper Sandler reiterated an Overweight rating for the stock, setting a price target of $92. The firm noted the benefits derived from pricing increases and demand pull-ins. Lake Street raised its price target to $94 from $90, citing a positive margin outlook. Additionally, William Blair maintained an Outperform rating following the company’s impressive first-quarter performance.
In corporate governance updates, Everpure held its annual stockholder meeting. During this meeting, three directors were elected to serve until the 2029 annual meeting. The combination of strong earnings, analyst optimism, and insider selling activity highlights the complex dynamics currently influencing the stock.